Microfluidic B Cell Isolation for Rapid Antibody Discovery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapy approaches for cancer, such as monoclonal antibody therapy and CAR-T therapy, face challenges in identifying optimal antibodies quickly enough to provide timely treatment, as they require extensive research and may not be effective within the limited window for preventing morbidity and mortality.
Innovation Solution
A method involving a microfluidic device to isolate and identify B cells from a patient's tumor sample that produce cancer-specific antibodies, allowing for rapid identification and use of these antibodies in therapeutic applications, including monoclonal antibodies or CAR-T therapeutics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of time
If conventional monoclonal antibody therapy or CAR-T therapy is used, then cancer treatment can be provided, but the identification and development process takes too long to be effective within the limited treatment window
Solution Approach 1:
The invention segments the complex antibody identification and development process into distinct modular steps: (1) isolating B cells directly from patient tumor tissue using microfluidic devices, (2) rapidly screening these cells for cancer-specific antibody production, and (3) immediately proceeding to therapeutic development. This segmentation enables parallel processing and eliminates sequential delays, reducing the overall timeline from years to months while maintaining treatment reliability.
Solution Approach 2:
The invention performs preliminary action by directly isolating and screening B cells from the patient's own tumor tissue before treatment begins. This preliminary identification of patient-specific antibody-producing cells eliminates the need for subsequent extensive screening and development phases, allowing therapeutic development to start immediately with known effective targets, thus ensuring treatment effectiveness within the limited window.
2Reliability
If extensive research investigation is conducted to identify optimal antibodies, then treatment effectiveness may be improved, but the treatment timeline is extended beyond the viable window for preventing morbidity and mortality
Solution Approach 1:
The invention extracts only the essential and most relevant B cells directly from the patient's tumor tissue that are producing cancer-specific antibodies. By using microfluidic isolation techniques, the method extracts precisely the antibody-producing cells of interest without needing to screen through large numbers of unrelated cells. This extraction approach ensures optimal antibody identification by focusing only on tumor-reactive B cells while dramatically reducing the time required compared to comprehensive screening methods.
Solution Approach 2:
The invention implements feedback by using the patient's own tumor tissue as the source material for isolating B cells. The tumor itself provides feedback about which antibodies are needed, as the B cells isolated from tumor tissue are already producing antibodies against that specific patient's cancer. This feedback mechanism ensures optimal antibody identification is achieved naturally through the body's own immune response, eliminating the need for extensive external research investigation.
3Reliability
If conventional methods are used to develop patient-specific antibodies, then effective treatment can be achieved, but the process requires extensive resources and time that are not available within the treatment window
Solution Approach 1:
The invention replaces conventional mechanical and manual methods of cell isolation and screening with microfluidic-based automated systems. These microfluidic devices use engineered flow patterns and physical principles to automatically isolate, capture, and screen B cells at high throughput. This substitution of mechanical systems with sophisticated microfluidic technology maintains patient-specific treatment efficacy while dramatically increasing productivity by processing thousands of cells simultaneously and identifying effective antibodies in days rather than months.
Data Source
AI summary
A method of preparing an antibody therapeutic is provided comprising: (a) providing a dissociated cell sample from at least one solid tumor sample obtained from a patient; (b) loading the dissociated cell sample into a microfluidic device having a flow region and at least one isolation region fluidically connected to the flow region; (c) moving at least one B cell from the dissociated cell sample into at least one isolation region in the microfluidic device, thereby obtaining at least one isolated B cell; and (d) using the microfluidic device to identify at least one B cell that produces antibodies capable of binding to cancer cells. The cancer cells can be the patient's own cancer cells. Also provided are methods of treating patients, methods of labeling or detecting cancer, engineered T or NK cells comprising antibodies or fragments thereof, and engineered antibody constructs.